Clemedi develops better diagnostic for infectious diseases. By combining DNA sequencing and machine learning algorithms we can recommend the appropriate antibiotic therapy within a day. This will improve the adequate use of theses lifesaving drugs and curb the spread of further antibiotic resistance. Our first product for tuberculosis has a world-wide market of 10M infections per year. Due to faster results, we shorten the quarantine time and decrease the overall treatment costs from 50k to 30k.